Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.

Published on Dec 1, 2017in Inflammatory Bowel Diseases4.261
· DOI :10.1097/MIB.0000000000001258
Christian P. Selinger2
Estimated H-index: 2
Christian P. Selinger25
Estimated H-index: 25
+ 6 AuthorsP John Hamlin12
Estimated H-index: 12
BACKGROUND: Virtual biologics clinics are often used to review patients with inflammatory bowel disease receiving biological therapy, with decisions whether to continue, switch, or stop therapy made based on review of symptoms, disease history, and investigations. We aimed to investigate whether therapeutic drug monitoring of infliximab (IFX) trough levels and anti-drug antibodies influences decision making within a virtual biologics clinic. METHODS: For all patients with inflammatory bowel disease receiving IFX maintenance therapy, 2 decisions were recorded in a preset format. The first decision was based on assessment of clinical details, with clinicians blinded to IFX trough levels and anti-drug antibodies. The second decision was made after unblinding of these data. RESULTS: Among 191 patients (mean age 40 years; 106 (55.5%) male), IFX trough levels were sub-therapeutic in 53 (27.7%) ( 6 mg/L). Anti-drug antibodies were detected in 58 (30.4%), and were >50 AU/mL in 26 (13.6%). Blinded treatment decisions were changed on unblinding these data in 56 cases (29.3%; P < 0.0001). Knowledge of these data led to 7 (3.7%) patients receiving intensified IFX, whereas 33 (17.3%) patients were able to either dose de-escalate or stop IFX. CONCLUSIONS: Basing decisions on therapeutic drug monitoring, rather than clinical acumen alone, led to a change in almost one-third of decisions made, offering considerable cost savings and reducing exposure to potentially toxic therapies. Routine therapeutic drug monitoring should be considered an integral part of annual biologics assessment (see Video Abstract, Supplemental Digital Content 1,
📖 Papers frequently viewed together
12 Citations
533 Citations
46 Citations
#1Andres Yarur (MCW: Medical College of Wisconsin)H-Index: 19
#2Vikram Kanagala (MCW: Medical College of Wisconsin)H-Index: 5
Last. Maria T. Abreu (UM: University of Miami)H-Index: 77
view all 11 authors...
SummaryBackground Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy. Aim To assess the correlation between perianal fistula healing and trough levels of infliximab. Methods In this cross-sectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24 weeks. We excluded patients who underwent a faecal diversion proc...
145 CitationsSource
#1Shomron Ben-Horin (TAU: Tel Aviv University)H-Index: 57
#2Yehuda Chowers (Rambam Health Care Campus)H-Index: 66
Last. Xavier Roblin (French Institute of Health and Medical Research)H-Index: 51
view all 10 authors...
Summary Background Low drug levels are associated with emerging loss of response to anti-TNF. However, this may not be the case in patients with long-term remission. Aim To investigate the outcome of anti-TNF discontinuation in patients with long-term remission and incidental undetectable drug levels. Methods A retrospective cohort study examining the duration of relapse-free survival in IBD patients in remission who discontinued infliximab or adalimumab having undetectable drug levels. Results ...
64 CitationsSource
#1Konstantinos Papamichael (Katholieke Universiteit Leuven)H-Index: 27
#2Niels Vande Casteele (Katholieke Universiteit Leuven)H-Index: 32
Last. Marc Ferrante (Katholieke Universiteit Leuven)H-Index: 59
view all 11 authors...
Background & Aims There are limited data on the effects of discontinuing infliximab therapy for Crohn's disease (CD). We investigated the long-term outcome of patients with CD who discontinued infliximab while in clinical remission, and searched for prognostic markers of continued remission after infliximab cessation. Methods We performed a retrospective, single-center study of 100 patients with CD who discontinued infliximab upon achieving clinical remission; 84 patients continued immunomodulat...
67 CitationsSource
#1Niels Vande Casteele (Katholieke Universiteit Leuven)H-Index: 32
#2Marc Ferrante (Katholieke Universiteit Leuven)H-Index: 59
Last. Severine Vermeire (Katholieke Universiteit Leuven)H-Index: 146
view all 10 authors...
Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission and whether continued concentration-based dosing is superior to clinically based dosing of infliximab for maintaining remission in patients with CD and UC. Methods We performed a 1-year randomized controlled trial at a tertiary referral cente...
533 CitationsSource
#1Henit Yanai (TAU: Tel Aviv University)H-Index: 20
#2Lev Lichtenstein (TAU: Tel Aviv University)H-Index: 5
Last. Shomron Ben-Horin (TAU: Tel Aviv University)H-Index: 57
view all 17 authors...
Background & Aims There is controversy about whether levels of anti–tumor necrosis factor (TNF) and antidrug antibodies (ADAs) are accurate determinants of loss of response to therapy. We analyzed the association between trough levels of anti-TNF agents or ADAs and outcomes of interventions for patients with loss of response to infliximab or adalimumab. Methods We performed a retrospective study of pediatric and adult patients with inflammatory bowel disease and suspected loss of response to ant...
199 CitationsSource
#1Byron P. Vaughn (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 24
#2Manuel Martinez-Vazquez (UCSD: University of California, San Diego)H-Index: 10
Last. Adam S. Cheifetz (Harvard University)H-Index: 47
view all 6 authors...
Background: Infliximab (IFX) is effective in the treatment of inflammatory bowel disease; however, the effect is often not durable. It is unknown if proactive therapeutic concentration monitoring (TCM) of IFX improves outcomes. Methods: This is a retrospective observational study examining the use of proactive TCM and titration of IFX to a target concentration for patients with inflammatory bowel disease in clinical remission at a tertiary care center. The primary aim was to describe the clinica...
143 CitationsSource
#1Bella Ungar (Sheba Medical Center)H-Index: 19
#2Yehuda Chowers (Rambam Health Care Campus)H-Index: 66
Last. Shomron Ben-Horin (Sheba Medical Center)H-Index: 57
view all 9 authors...
Objective To characterise the temporal evolution of antibodies to infliximab (ATI). Design Prospective observational study of infliximab-treated patients with inflammatory bowel disease between 2009 and 2012. Interventions Trough levels of infliximab and ATI were measured before each infusion by anti-λ ELISA. Patients were monitored for disease activity by clinical activity indexes and for dose-intensification or infliximab cessation. The occurrence of transient ATI disappearing spontaneously wi...
218 CitationsSource
#1Reena Khanna (Robarts Research Institute)H-Index: 29
#2Bernie D. Sattin (Janssen Pharmaceutica)H-Index: 4
Last. Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
view all 20 authors...
SummaryBackground Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy. Aim The evidence supporting the use of therapeutic drug monitoring (TDM) based clinical algorithms for infliximab (IFX) and their role in clinical practice will be discussed. Methods The literature was reviewed to identify relevant articles on th...
84 CitationsSource
#1Fernando Velayos (UCSF: University of California, San Francisco)H-Index: 30
#2James G. Kahn (UCSF: University of California, San Francisco)H-Index: 87
Last. Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
view all 4 authors...
Background & Aims Patients with Crohn's disease who become unresponsive to therapy with tumor necrosis factor antagonists are managed initially with either empiric dose escalation or testing-based strategies. The comparative cost effectiveness of these 2 strategies is unknown. We investigated whether a testing-based strategy is more cost effective than an empiric dose-escalation strategy. Methods A decision analytic model that simulated 2 cohorts of patients with Crohn's disease compared outcome...
134 CitationsSource
#1Axel DignassH-Index: 46
#2James O. LindsayH-Index: 57
Last. Gert Van AsscheH-Index: 92
view all 17 authors...
### 5.1 General When deciding the appropriate treatment strategy for active ulcerative colitis one should consider the activity, distribution (proctitis, left-sided, extensive1), and pattern of disease. The disease pattern includes relapse frequency, course of disease, response to previous medications, side-effect profile of medication and extra-intestinal manifestations. The age at onset and disease duration may also be important factors. #### 5.1.1 Disease activity The principal disease activi...
1,074 CitationsSource
Cited By12
#1Yang Wu (UNSW: University of New South Wales)H-Index: 1
#2Amy Wen (UNSW: University of New South Wales)
Last. Susan J. Connor (UNSW: University of New South Wales)H-Index: 21
view all 9 authors...
#1Alexander Eser (Medical University of Vienna)
#1Alexander Eser (Medical University of Vienna)H-Index: 12
Last. Diane R. MouldH-Index: 20
view all 6 authors...
Treatment of patients with biologics such as infliximab may trigger development of antidrug antibodies, which are associated with faster drug clearance, reduced treatment efficacy, and increased risk of infusion-related reactions. The aim of this study was to identify predictors of baseline infliximab clearance and early antidrug antibody formation. Pharmacokinetic and pharmacokinetic/pharmacodynamic models for infliximab were developed using 21 178 observations from 859 patients from the PLANET...
1 CitationsSource
#1Patrick F. van Rheenen (UG: University of Groningen)H-Index: 22
#2Marina Aloi (Sapienza University of Rome)H-Index: 30
Last. Frank M. Ruemmele (Paris V: Paris Descartes University)H-Index: 65
view all 25 authors...
OBJECTIVE We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn's disease [CD]. METHODS We formed 10 working groups and formulated 17 PICO-structured clinical questions [Patients, Intervention, Comparator, and Outcome]. A systematic literature search from January 1, 1991 to March 19, 2019 was conducted by a medical librarian using MEDLINE, EMBASE, and Cochrane Central databases. A shortlist of 30 provisional statements were f...
34 CitationsSource
PURPOSE Infliximab (IFX) therapy in inflammatory bowel disease (IBD) is associated with loss of response in half the patients, due to complex pharmacokinetic and immunological factors. Dashboard's Bayesian algorithms use information from model and individual multivariate determinants of IFX concentration and can predict dose and dosing interval. AIM To compare measured IFX concentrations in our laboratory with values predicted by iDose dashboard system and report its efficacy in managing patient...
The published online version contain error for the author's name "Kiran Peddi" was incorrectly presented as "Kiran Peddy".
1 CitationsSource
#1Ashish Srinivasan (Monash University)H-Index: 3
#2Daniel R. van Langenberg (Monash University)H-Index: 15
Last. Mark G. Ward (Monash University)H-Index: 10
view all 6 authors...
BACKGROUND: Virtual clinics represent a novel model of care in inflammatory bowel disease. Their effectiveness in promoting high quality use of biologic therapy and facilitating a treat-to-target approach is unknown. AIM: To evaluate clinical and process-driven outcomes in a virtual clinic compared to standard outpatient care amongst patients receiving intensified anti-TNF therapy for secondary loss of response. METHODS: We performed a retrospective multi-centre, parallel, observational cohort s...
4 CitationsSource
#1Marco Vincenzo Lenti (UNIPV: University of Pavia)H-Index: 16
#2S. Cococcia (UNIPV: University of Pavia)H-Index: 6
Last. Christian P. Selinger (Leeds Teaching Hospitals NHS Trust)H-Index: 2
view all 5 authors...
Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, is an immune-mediated, chronic relapsing disorder characterised by severe gastrointestinal symptoms that dramatically impair patients’ quality of life, affecting psychological, physical, sexual, and social functions. As a consequence, patients suffering from this condition may perceive social stigmatisation, which is the identification of negative attributes that distinguish a person as different and worthy of sep...
6 CitationsSource
#1Neasa Mc Gettigan (National University of Ireland, Galway)H-Index: 1
#2Aine Keogh (National University of Ireland, Galway)H-Index: 2
Last. Eoin Slattery (National University of Ireland, Galway)H-Index: 10
view all 6 authors...
3 CitationsSource
#1Konstantinos Papamichael (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 27
#2Adam S. Cheifetz (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 47
Last. Corey A. Siegel (Dartmouth–Hitchcock Medical Center)H-Index: 51
view all 16 authors...
Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and provided expert opinion regarding the clinical utility of TDM for biologic therapies in IBD. Methods We used a modified Delphi method to establish consensus. A comprehensive literature review was performed regarding the use of TDM of biologic therapy in IBD and presented to international IBD specialists. Subsequently, 28 st...
87 CitationsSource
#1Christian P. Selinger (Leeds Teaching Hospitals NHS Trust)H-Index: 25
#2Isabel Carbery (Leeds Teaching Hospitals NHS Trust)H-Index: 2
Last. Jamal Al-Asiry (Leeds Teaching Hospitals NHS Trust)H-Index: 1
view all 3 authors...
The treatment of inflammatory bowel disease has changed dramatically over the last two decades. The arrival of infliximab as the first biological medicine for inflammatory bowel disease revolutionized its management. Since then the armamentarium of biological medicines for inflammatory bowel disease has grown to five drugs in three different classes. This article highlights the different mechanisms of action and describes the key evidence for their use including drug safety profiles. Furthermore...
1 CitationsSource